Inhibition of GS with an oral small-molecule inhibitor (GSI) leads to a thirtyfold increase of BCMA expression on myeloma cells and the combination of GSI with concurrent BCMA targeted therapy is evaluated in a clinical trial (#NCT03502577). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.